From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF)

S Couraud, A B Cortot, L Greillier, V Gounant, B Mennecier, N Girard, B Besse, L Brouchet, O Castelnau, P Frappé, G R Ferretti, L Guittet, A Khalil, P Lefebure, F Laurent, S Liebart, O Molinier, E Quoix, M-P Revel, B Stach, P-J Souquet, P Thomas, J Trédaniel, E Lemarié, G Zalcman, F Barlési, B Milleron, French lung cancer screening statement taskforce, groupe d'Oncologie de langue française, S Couraud, A B Cortot, L Greillier, V Gounant, B Mennecier, N Girard, B Besse, L Brouchet, O Castelnau, P Frappé, G R Ferretti, L Guittet, A Khalil, P Lefebure, F Laurent, S Liebart, O Molinier, E Quoix, M-P Revel, B Stach, P-J Souquet, P Thomas, J Trédaniel, E Lemarié, G Zalcman, F Barlési, B Milleron, French lung cancer screening statement taskforce, groupe d'Oncologie de langue française

Abstract

Background: Despite advances in cancer therapy, mortality is still high except in early-stage tumors, and screening remains a challenge. The randomized National Lung Screening Trial (NLST), comparing annual low-dose computed tomography (LDCT) and chest X-rays, revealed a 20% decrease in lung-cancer-specific mortality. These results raised numerous questions. The French intergroup for thoracic oncology and the French-speaking oncology group convened an expert group to provide a coherent outlook on screening modalities in France.

Methods: A literature review was carried out and transmitted to the expert group, which was divided into three workshops to tackle specific questions, with responses presented in a plenary session. A writing committee drafted this article.

Results: The multidisciplinary group favored individual screening in France, when carried out as outlined in this article and after informing subjects of the benefits and risks. The target population involves subjects aged 55-74 years, who are smokers or have a 30 pack-year smoking history. Subjects should be informed about the benefits of quitting. Screening should involve LDCT scanning with specific modalities. Criteria for CT positivity and management algorithms for positive examinations are given.

Conclusions: Individual screening requires rigorous assessment and precise research in order to potentially develop a lung-cancer screening policy.

Figures

Figure 1.
Figure 1.
Management algorithm for the interpretation of scans showing a solid nodule.
Figure 2.
Figure 2.
Management of solid indeterminate nodules.
Figure 3.
Figure 3.
Management of ground-glass opacity nodule.

References

    1. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355(17):1763–1771.
    1. Raz DJ, Zell JA, Ou S-HI, et al. Natural History of Stage I Non-Small Cell Lung Cancer: Implications for Early Detection. Chest. 2007;132(1):193–199.
    1. Nawa T, Nakagawa T, Mizoue T, et al. Long-term prognosis of patients with lung cancer detected on low-dose chest computed tomography screening. Lung Cancer. 2012;75(2):197–202.
    1. Frost JK, Ball WC, Jr, Levin ML, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis. 1984;130(4):549–554.
    1. Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst. 2000;92(16):1308–1316.
    1. Oken MM, Hocking WG, Kvale PA, et al. Screening by Chest Radiograph and Lung Cancer Mortality: The Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Trial. JAMA: The Journal of the American Medical Association. 2011;306(17):1865–1873.
    1. The National Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Eng J Med. 2011;365(5):395–409.
    1. National Lung Screening Trial Research Team. The National Lung Screening Trial: Overview and Study Design. Radiology. 2010;258(1):243–253.
    1. Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009;180(5):445–453.
    1. Blanchon T, Bréchot J-M, Grenier PA, et al. Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR) Lung Cancer. 2007;58(1):50–58.
    1. Hocking WG, Hu P, Oken MM, et al. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst. 2010;102(10):722–731.
    1. Veronesi G, Bellomi M, Mulshine JL, et al. Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer. 2008;61(3):340–349.
    1. Veronesi G, Bellomi M, Scanagatta P, et al. Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program. The Journal of Thoracic and Cardiovascular Surgery. 2008;136(3):611–617.
    1. Veronesi Giulia . ; Amsterdam: 2011. Diagnostic Performance of annual LD-CT screenign for lung cancer after five years, MO05.02 [Internet] [cited 2012 Jul 24] .
    1. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med. 2009;361(23):2221–2229.
    1. Pedersen JH, Ashraf H, Dirksen A, et al. The Danish randomized lung cancer CT screening trial–overall design and results of the prevalence round. J Thorac Oncol. 2009;4(5):608–614.
    1. Lopes Pegna A, Picozzi G, Mascalchi M, et al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer. 2009;64(1):34–40.
    1. Baldwin DR, Duffy SW, Wald NJ, et al. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax. 2011;66(4):308–313.
    1. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON) Int J Cancer. 2007;120(4):868–874.
    1. Paci E. Abstract SS03-03: The ITALUNG study and the state of art of randomized screening trials in Europe. Cancer Prevention Research. 2011;4(Suppl 10) .
    1. Henschke CI, Boffetta P, Gorlova O, et al. Assessment of lung-cancer mortality reduction from CT Screening. Lung Cancer. 2011;71(3):328–332.
    1. Veronesi Gulia. Amsterdam: 2011. Long-Term outcomes of a pilot CT screening for lung cancer: 10-years results, MO05.07 [Internet] [cited 2012 Jul 23] .
    1. Veronesi G, Maisonneuve P, Spaggiari1 L, et al. Long-term outcomes of a pilot CT screening for lung cancer. Ecancermedicalscience. 2010;4:186.
    1. France, ANAES. Guide Méthodologique: Comment Évaluer A Priori Un Programme De Dépistage? [Internet] Saint denis La Plaine: Agence Nationale d'Accréditation et d'Evaluation en Santé; 2004 Mai Available from .
    1. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21(3):308–315.
    1. Maisonneuve P, Bagnardi V, Bellomi M, et al. Lung cancer risk prediction to select smokers for screening CT––a model based on the Italian COSMOS trial. Cancer Prev Res (Phila) 2011;4(11):1778–1789.
    1. Henschke CI, Yankelevitz DF, McCauley DI, et al. Guidelines for the use of spiral computed tomography in screening for lung cancer. Eur Respir J Suppl. 2003;39:45s–51s.
    1. Field JK, Smith RA, Aberle DR, et al. International association for the study of lung cancer computed tomography screening workshop 2011 report. J Thorac Oncol. 2012;7(1):10–19.
    1. Kim MJ, Park CH, Choi SJ, et al. Multidetector computed tomography chest examinations with low-kilovoltage protocols in adults: effect on image quality and radiation dose. J Comput Assist Tomogr. 2009;33(3):416–421.
    1. Manowitz A, Sedlar M, Griffon M, et al. Use of BMI guidelines and individual dose tracking to minimize radiation exposure from low-dose helical chest CT scanning in a lung cancer screening program. Acad Radiol. 2012;19(1):84–88.
    1. Jankowski A, Martinelli T, Timsit JF, et al. Pulmonary nodule detection on MDCT images: evaluation of diagnostic performance using thin axial images, maximum intensity projections, and computer-assisted detection. Eur Radiol. 2007;17(12):3148–3156.
    1. Wormanns D, Ludwig K, Beyer F, et al. Detection of pulmonary nodules at multirow-detector CT: effectiveness of double reading to improve sensitivity at standard-dose and low-dose chest CT. Eur Radiol. 2005;15(1):14–22.
    1. Wang Y, van Klaveren RJ, de Bock GH, et al. No benefit for consensus double reading at baseline screening for lung cancer with the use of semiautomated volumetry software. Radiology. 2012;262(1):320–326.
    1. France, IRSN. Paris: Institut de Radioprotection et de Sureté Nucléaire (IRSN); 2011. Bilan de l’état radiologique de l'environnement français en 2009 - Synthèse des résultats des réseaux de surveillance de l'IRSN [Internet] .
    1. France, IRSN. Paris: Institut de Radioprotection et de Sureté Nucléaire (IRSN); 2010. Doses délivrées aux patients en scanographie et en radiologie conventionnelle - Résultats d'une enquête multicentrique en secteur public [Internet] Report No.: DRPH/SER No 2010-12 .
    1. Kong CY, Lee JM, McMahon PM, et al. Using radiation risk models in cancer screening simulations: important assumptions and effects on outcome projections. Radiology. 2012;262(3):977–984.
    1. Mascalchi M, Mazzoni LN, Falchini M, et al. Dose exposure in the ITALUNG trial of lung cancer screening with low-dose CT. Br J Radiol. 2012;85(1016):1134–1139.
    1. Zerhouni EA, Stitik FP, Siegelman SS, et al. CT of the pulmonary nodule: a cooperative study. Radiology. 1986;160(2):319–327.
    1. Ahn MI, Gleeson TG, Chan IH, et al. Perifissural Nodules Seen at CT Screening for Lung Cancer. Radiology. 2010;254(3):949–956.
    1. Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer. 2006;54(2):177–184.
    1. Godoy MCB, Naidich DP. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. Radiology. 2009;253(3):606–622.
    1. Takashima S, Sone S, Li F, et al. Indeterminate solitary pulmonary nodules revealed at population-based CT screening of the lung: using first follow-up diagnostic CT to differentiate benign and malignant lesions. AJR Am J Roentgenol. 2003;180(5):1255–1263.
    1. France, INCa. © Cancer du poumon, Bilan initial [Internet] Boulogne Billancourt: INCa––Institut National du Cancer; juin 20101 p. 46 .
    1. van't Westeinde SC, de Koning HJ, Thunnissen FB, et al. The role of the 18f-fluorodeoxyglucose-positron emission tomography scan in the Nederlands Leuvens Longkanker screenings Onderzoek lung cancer screening trial. J Thorac Oncol. 2011;6(10):1704–1712.
    1. van ‘t Westeinde SC, Horeweg N, Vernhout RM, et al. The role of conventional bronchoscopy in the work-up of suspicious CT screen detected pulmonary nodules. Chest. 2012 Feb 2 [cited 2012 Mar 9] [Epub ahead of print]
    1. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 2011;6(2):244–285.
    1. Rami-Porta R, Tsuboi M. Sublobar resection for lung cancer. Eur Respir J. 2009;33(2):426–435.
    1. France, SFCTCV, France, INCA Cancer primitif non à petites cellules du poumon?: pratiques chirurgicales. Recommandations; Rapport intégral. [Internet]. Société Française de Chirurgie Thoracique et Cardio-Vasculaire et Institut National du Cancer .
    1. Becker N, Delorme S, Kauczor H. LUSI: the german component of the european trial on the efficacy of multisclice-CT for the early detection of lung cancer. Onkologie. 2008;31(suppl 1):130.
    1. Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer screening Trial: status after five annual screening rounds with low-dose CT. Thorax. 2012;67(4):296–301.
    1. Stefanek ME. Uninformed compliance or informed choice? A needed shift in our approach to cancer screening. J Natl Cancer Inst. 2011;103(24):1821–1826.
    1. Wegwarth O, Schwartz LM, Woloshin S, et al. Do physicians understand cancer screening statistics? A national survey of primary care physicians in the United States. Ann Intern Med. 2012;156(5):340–349.
    1. Wood DE, Eapen GA, Ettinger DS, et al. Lung cancer screening. J Natl Compr Canc Netw. 2012;10(2):240–265.
    1. Italian lung cancer CT screening trial workshop. International workshop on randomized lung cancer screening trials. State of the art in Europe after early conclusion of the US National Lung Screening Trial [Internet]; 2011. Osservatorio Nazionale Screening Official Website [cited 2012 Jul 27]. Available from .
    1. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418–2429.
    1. Bellizzi KM, Breslau ES, Burness A, et al. Prevalence of cancer screening in older, racially diverse adults: still screening after all these years. Arch Intern Med. 2011;171(22):2031–2037.
    1. Morère J-F, Pivot X, Viguier J, et al. Breast cancer screening in women aged 50–74 years: is there room for improvement? Eur J Cancer Prev. 2011;20(Suppl 1):S8–S12.
    1. Pornet C, Dejardin O, Morlais F, et al. Socioeconomic and healthcare supply statistical determinants of compliance to mammography screening programs: a multilevel analysis in Calvados, France. Cancer Epidemiol. 2010;34(3):309–315.
    1. Aberle DR, Adams AM, Berg CD, et al. Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst. 2010;102(23):1771–1779.
    1. Booth CM, Li G, Zhang-Salomons J, et al. The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada. Cancer. 2010;116(17):4160–4167.
    1. Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2008;98(2):270–276.
    1. McMahon PM, Kong CY, Bouzan C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol. 2011;6(11):1841–1848.
    1. Ferketich AK, Otterson GA, King M, et al. A pilot test of a combined tobacco dependence treatment and lung cancer screening program. Lung Cancer. 2012;76(2):211–215.
    1. van der Aalst CM, van Klaveren RJ, van den Bergh KAM, et al. The impact of a lung cancer computed tomography screening result on smoking abstinence. Euro Respir J. 2010;37(6):1466–1473.
    1. Dinnes J, Moss S, Melia J, et al. Effectiveness and cost-effectiveness of double reading of mammograms in breast cancer screening: findings of a systematic review. Breast. 2001;10(6):455–463.
    1. Ciatto S, Ambrogetti D, Bonardi R, et al. Second reading of screening mammograms increases cancer detection and recall rates. Results in the Florence screening programme. J Med Screen. 2005;12(2):103–106.
    1. Gierada DS, Garg K, Nath H, et al. CT quality assurance in the Lung Screening Study Component of the National Lung Screening Trial: implications for multicenter imaging trials. Am J Roentgenol. 2009;193(2):419–424.
    1. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA. 2011;108(9):3713–3718.
    1. Bianchi F, Nicassio F, Marzi M, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011;3(8):495–503.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever